FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Elaine Chang(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Eias Zahalka(Center for Drug Evaluation and Research), Peter Waldron(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Pengfei Song(Henan University), Marc R. Theoret(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Tiffany K. Ricks(United States Food and Drug Administration), Vicky Hsu(Center for Drug Evaluation and Research), Chana Weinstock(United States Food and Drug Administration), Fang Li(Jiangsu Province Hospital), Lijun Zhang(Tongji University), Jingyu Yu(Center for Drug Evaluation and Research), Rosane Charlab, Yutao Gong(Center for Drug Evaluation and Research), Sarah E. Dorff(United States Food and Drug Administration)
Cited by 186
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k